Patrick J. Heron - 05 Jun 2026 Form 4/A - Amendment Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 12 Jun 2026, 17:55:18 UTC
Original report date: 09 Jun 2026
Prior SEC filing: 05 Jun 2026
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, Attorney-in-Fact for Patrick J. Heron

Key filing fact

Patrick J. Heron filed Form 4/A - Amendment for Arcutis Biotherapeutics, Inc. (ARQT) on 12 Jun 2026.

Key facts

This page summarizes Patrick J. Heron's Form 4/A - Amendment filing for Arcutis Biotherapeutics, Inc. (ARQT).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 17:55.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001365617 Primary reporting owner

Heron Patrick J

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, Attorney-in-Fact for Patrick J. Heron
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 27,448
Date: 05 Jun 2026
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Due to a scrivener's error on the Reporting Person's Form 4 filed on June 9, 2026, the number of shares of common stock indirectly held by the Reporting Person through Frazier Life Sciences X, L.P. reflected a discrepancy that inadvertently understated the Reporting Person's indirect beneficial ownership by 2,646 shares. The correct number of shares so indirectly held by the Reporting Person is reflected in this Form 4/A.

Footnote F2

The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.